tbuckley/cabot-search huggingface dataset:
Recombinant human endostatin combined carboplatin plus etoposide for advanced small-cell lung cancer.
Authors: Jianhua Chen, Yongzhong Luo, Wenwei Zhou, Hui Zhou, Wei Wang
Journal: Journal of Clinical Oncology (2014)

e18554 Background: The aim of our study was to analyze the clinical efficacy of recombinant human endostatin (endostar) combined with carboplatin plus etoposide (CE) regimen on patients with advanced small-cell lung cancer (SCLC). Methods: Forty-three patients with advanced SCLC were enrolled and divided into observation group (n=19) and control group (n=24). The patients in control group received CE regimen for 2 cycles, while those in observation group were added endostar on the basis of treatment in control group. The short-term effect and safety were compared between two groups after two cycles of treatment at least. Results: The response rate in observation group came up to 84.2%, which showed significant difference by comparison to control group (p<0.05). The median progression-free survivals (MPFS) in observation group and control group were 7.9 and 6.1 months, respectively, with significant difference (p<0.05). The median survivals in observation group and control group were 11.1 and 11.0 months, respectively, without significant difference (p>0.05). Besides, there was no significant difference between two groups in terms of toxicity induced by chemotherapeutics (p>0.05). Conclusions: Endostar combined with CE regimen in the treatment of advanced SCLC has better short-term effect and tolerance.
TCTAP C-019 The Clinical History of a 88 Year-old Female with Acute Coronary Syndrome with ST Elevation and Frederick’s Syndrome
Authors: Alexey Biryukov, Ekaterina Leonidovna Zaslavskaya, Kirill Alexeevich Smirnov, Andrei Aleksandrovich Voronkov, Dmitriy Vladimirovich Ovcharenko
Journal: Journal of the American College of Cardiology (2017)
Increasing value and reducing waste in stroke research
Authors: Eivind Berge, Rustam Al-Shahi Salman, H Bart van der Worp, Christian Stapf, Peter Sandercock, Nikola Sprigg, Malcolm R Macleod, Peter J Kelly, Paul J Nederkoorn, Gary A Ford, Marcel Arnold, Eivind Berge, Exuperio Diez-Tejedor, Dalius Jatuzis, Peter J Kelly, Derk W Krieger, Paul J Nederkoorn, Peter Sandercock, Christian Stapf, Christian Weimar, Gary A Ford, Rustam Al-Shahi Salman
Journal: The Lancet Neurology (2017)
MUSCULOSKELETAL INJURY RATES IN MULTIDAY MARATHON RUNNERS PERFORMING A REPEAT COURSE
Authors: Katie Small, Adam Smith, Relph Nicola
Journal: British Journal of Sports Medicine (2017)

Background Ultramarathon events are increasingly popular amongst non-elite athletes. However, there is little research investigating musculoskeletal injury rates, specifically multiday events using the same racing route. Objective To describe musculoskeletal injury rates in runners completing ten marathons over ten consecutive days. Design Observational. Setting Sports-injury clinic. Participants 27 athletes entered the study (age 45.1±7.47 yrs, mass 74.5±12.39 kg, years running 11.6±9.42 yrs, average weekly mileage 41.9±12.72 miles). 26 athletes completed all 10 marathons on a repeat, anti-clockwise, circular road course. One athlete withdrew due to serious injury. Main Outcome Measurements Musculoskeletal injuries were recorded by trained medical staff three times each day. An injury audit questionnaire was used to document injury rate, type and location. Injuries were defined as a specific musculoskeletal abnormality that the runner perceived to effect performance. Results 26 athletes sustained 108 injuries, averaging 4 injuries per athlete. 89% of injuries involved the lower extremity, 24.1% occurred in the foot, 18.5% the hip/buttock, 16.7% the ankle and 16.7% in the lower leg. The most common injuries were blisters (15.7%), Achilles tendinitis (11.1%), medial tibial stress syndrome (10.2%), iliotibial band syndrome (ITBS) (9.3%) and low back pain (LBP) (9.3%). 64.3% of injuries were sustained to the left limb. Chi-squared analysis revealed more injuries in days 1–3 than days 4–6 ( p =0.013) and days 7–10 ( p =0.001). Conclusions Lower extremity injuries are highly likely in multiday marathon running; the most common being blisters, Achilles tendinitis, medial tibial stress syndrome, ITBS and LBP. Athletes entering these events should engage in appropriate injury prevention programmes. The majority of injuries were sustained to the left limb and during the first three days. Multiday marathon event organisers should consider alternating route direction to reduce injury risk; potentially the result of prolonged, altered gait biomechanics. However, further investigation of injury risk factors using larger sample sizes is required.
Health secretary orders inquiry into babies’ deaths at Shrewsbury and Telford
Authors: Anne Gulland
Journal: BMJ (2017)

England’s health secretary, Jeremy Hunt, has ordered an inquiry into the care of babies at an NHS trust after a BBC investigation highlighted several avoidable deaths.

Information obtained by the BBC shows that there have been at least seven avoidable deaths of babies at Shrewsbury and Telford Hospital NHS Trust since 2013, with at least two more suspicious deaths.

In a statement a Department of Health spokesman said, “Earlier this year, the health secretary asked NHS regulators to undertake an investigation at Shrewsbury and Telford Hospital NHS Trust in light of disclosures that in a number of tragic cases standards of care fell far below …
Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology
Authors: Vahid Montazerhodjat, Shomesh E. Chaudhuri, Daniel J. Sargent, Andrew W. Lo
Journal: JAMA Oncology (2017)

Randomized clinical trials (RCTs) currently apply the same statistical threshold of alpha = 2.5% for controlling for false-positive results or type 1 error, regardless of the burden of disease or patient preferences. Is there an objective and systematic framework for designing RCTs that incorporates these considerations on a case-by-case basis?To apply Bayesian decision analysis (BDA) to cancer therapeutics to choose an alpha and sample size that minimize the potential harm to current and future patients under both null and alternative hypotheses.We used the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database and data from the 10 clinical trials of the Alliance for Clinical Trials in Oncology.The NCI SEER database was used because it is the most comprehensive cancer database in the United States. The Alliance trial data was used owing to the quality and breadth of data, and because of the expertise in these trials of one of us (D.J.S.).The NCI SEER and Alliance data have already been thoroughly vetted. Computations were replicated independently by 2 coauthors and reviewed by all coauthors.Our prior hypothesis was that an alpha of 2.5% would not minimize the overall expected harm to current and future patients for the most deadly cancers, and that a less conservative alpha may be necessary. Our primary study outcomes involve measuring the potential harm to patients under both null and alternative hypotheses using NCI and Alliance data, and then computing BDA-optimal type 1 error rates and sample sizes for oncology RCTs.We computed BDA-optimal parameters for the 23 most common cancer sites using NCI data, and for the 10 Alliance clinical trials. For RCTs involving therapies for cancers with short survival times, no existing treatments, and low prevalence, the BDA-optimal type 1 error rates were much higher than the traditional 2.5%. For cancers with longer survival times, existing treatments, and high prevalence, the corresponding BDA-optimal error rates were much lower, in some cases even lower than 2.5%.Bayesian decision analysis is a systematic, objective, transparent, and repeatable process for deciding the outcomes of RCTs that explicitly incorporates burden of disease and patient preferences.
Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.
Authors: Christina Fotopoulou, Ioana Braicu, Ignace B. Vergote, Isabelle Cadron, Frederic Amant, Radoslav Chekerov, Dan Cacsire Castillo-Tong, Paul Speiser, Rolf Richter, Nicole Concin, Christian Marth, Sven Mahner, Fabian Trillsch, Robert Zeillinger, Jalid Sehouli
Journal: Journal of Clinical Oncology (2012)

5071 Background: The international scenery around optimal primary treatment of advanced ovarian cancer (AOC) patients (pts) is currently being discussed, with large discrepancies and heterogeneity still existing between the national guidelines worldwide. Aim of the present study was to evaluate the differences in outcome of AOC-pts after primary (PDS) versus interval-debulking-surgery (IDS) based on a prospectively assessed multicenter data set. Methods: Overall outcome was analyzed from the OVCAD database; a prospective, observational, multicenter project. AOC-pts who underwent surgery in five specialized gynecological cancer centers across three European countries between 02/2005 and 12/2008 were evaluated. Overall (OS) and progression free survival (PFS) were calculated by Kaplan-Meier-curves. Univariate and Cox-regression-analysis were applied. Results: Overall, 256 AOC pts (FIGO-stage III/IV) were evaluated. Fifty pts (19.5%) underwent IDS and 206 pts (80.5%) PDS. Despite the non-randomized setting both groups were well balanced in terms of FIGO-stage, grading, histological subtype and presence of ascites. Different selection criteria were however present for each center. PDS pts presented significantly higher rates of intestinal resection (44.2% vs.24%; p=0.01) and lymphonodectomy compared to IDS ones (72.3%vs.48%; p=0.001), by equivalent complete tumor resection rates (67.5% vs.68%; p=0.82). Platinum response was significantly higher in PDS vs. IDS pts (80.6% vs. 54%; p&lt;0.001). 3-years OS was with 66.7% (95%CI: 60.2-73.2%) significantly better in PDS- versus 48.3% (95%CI: 34.2-62.5%) in IDS pts (p&lt;0.001). Also 2-years PFS was with 31.9% (95%CI:24.8-39.1%) significantly higher in PDS- vs. 11.4% (95%CI: 0.9-22%) in IDS-pts (p&lt;0.001). In multivariate analysis PDS, but not age, ascites, FIGO-stage, grading, histology or residual tumor were of prognostic significance for platinum response. In addition, multivariate analysis identified PDS and no residual tumor to positively and ascites to negatively affect OS and PFS. Conclusions: PDS appears to be associated with a more favorable outcome compared to IDS in highly specialized centers according to this non-randomized data set.
Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors
Authors: Theresa H. M. Keegan, Archie Bleyer, Aaron S. Rosenberg, Qian Li, Melanie Goldfarb
Journal: JAMA Oncology (2017)

Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age.To assess the survival impact of SPMs in adolescents and young adults (AYAs) (15-39 years) compared with that of pediatric (<15 years) and older adult (≥40 years) patients with the same SPMs.This was a population-based, retrospective cohort study of patients with cancer in 13 Surveillance, Epidemiology and End Results regions in the United States diagnosed from 1992 to 2008 and followed through 2013. Data analysis was performed between June 2016 and January 2017.Five-year relative survival was calculated overall and for each cancer occurring as a PM or SPM by age at diagnosis. The impact of SPM status on cancer-specific death was examined using multivariable Cox proportional hazards regression.A total of 15 954 pediatric, 125 750 AYAs, and 878 370 older adult patients diagnosed as having 14 cancers occurring as a PM or SPM were included. Overall, 5-year survival after an SPM was 33.1% lower for children, 20.2% lower for AYAs, and 8.3% lower for older adults compared with a PM at the same age. For the most common SPMs in AYAs, the absolute difference in 5-year survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary breast carcinoma, 15% for secondary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma. Survival by SPM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer. Adolescents and young adults with secondary Hodgkin lymphoma (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]); breast carcinoma (2.1 [1.8-2.4]); acute myeloid leukemia (1.9 [1.5-2.4]); and central nervous system cancer (1.8 [1.2-2.8]) experienced worse survival compared with AYAs with the same PMs.The adverse impact of SPMs on survival is substantial for AYAs and may partially explain the relative lack of survival improvement in AYAs compared with other age groups. The impact of a particular SPM diagnosis on survival may inform age-specific prevention, screening, treatment, and survivorship recommendations.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Authors: Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Markus F Neurath, Stefan Schreiber, Paul Scholl, Chandrasena Pamulapati, Bojan Lalovic, Sudha Visvanathan, Steven J Padula, Ivona Herichova, Adina Soaita, David B Hall, Wulf O Böcher
Journal: The Lancet (2017)
ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery
Authors: Haochen Xu, Yongliang Cao, Xing Yang, Ping Cai, Lijing Kang, Ximin Zhu, Haiyu Luo, Lu Lu, Lixiang Wei, Xiaofei Bai, Yuanbo Zhu, Bing-Qiao Zhao, Wenying Fan
Journal: Blood (2017)
Monitoring of Pneumothorax Appearance with Electrical Impedance Tomography during Recruitment Maneuvers
Authors: Caio C. A. Morais, Roberta R. De Santis Santiago, José R. B. de Oliveira Filho, Adriana S. Hirota, Pedro H. D. Pacce, Juliana C. Ferreira, Erick D. L. B. Camargo, Marcelo B. P. Amato, Eduardo L. V. Costa
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Authors: Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care (2017)
Liquid biopsy: a step forward towards precision medicine in urologic malignancies
Authors: Ashley Di Meo, Jenni Bartlett, Yufeng Cheng, Maria D. Pasic, George M. Yousef
Journal: Molecular Cancer (2017)

There is a growing trend towards exploring the use of a minimally invasive "liquid biopsy" to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation and mutations. Other prospective liquid biopsy markers include circulating tumor cells, circulating RNAs (miRNA, lncRNAs and mRNAs), cell-free proteins, peptides and exosomes have also emerged as non-invasive cancer biomarkers. These circulating molecules can be detected in various biological fluids, including blood, urine, saliva and seminal plasma. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. Molecular profiling of circulating molecules has been a stepping-stone to the successful introduction of several non-invasive multi-marker tests into the clinic. In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and discuss the potential utility other circulating molecules. We will also discuss the challenges and limitations facing non-invasive cancer biomarker discovery and the benefits of this growing area of translational research.
Creation of an Internal Teledermatology Store-and-Forward System in an Existing Electronic Health Record
Authors: Zachary A. Carter, Shauna Goldman, Kristen Anderson, Xiaxiao Li, Linda S. Hynan, Benjamin F. Chong, Arturo R. Dominguez
Journal: JAMA Dermatology (2017)

External store-and-forward (SAF) teledermatology systems operate separately from the primary health record and have many limitations, including care fragmentation, inadequate communication among clinicians, and privacy and security concerns, among others. Development of internal SAF workflows within existing electronic health records (EHRs) should be the standard for large health care organizations for delivering high-quality dermatologic care, improving access, and capturing other telemedicine benchmark data. Epic EHR software (Epic Systems Corporation) is currently one of the most widely used EHR system in the United States, and development of a successful SAF workflow within it is needed.To develop an SAF teledermatology workflow within the Epic system, the existing EHR system of Parkland Health and Hospital System (Dallas, Texas), assess its effectiveness in improving access to care, and validate its reliability; and to evaluate the system's ability to capture meaningful outcomes.Electronic consults were independently evaluated by 2 board-certified dermatologists, who provided diagnoses and treatment plans to primary care physicians (PCPs). Results were compared with in-person referrals from May to December 2013 from the same clinic (a community outpatient clinic in a safety-net public hospital system). Patients were those 18 years or older with dermatologic complaints who would have otherwise been referred to dermatology clinic.Median time to evaluation; percentage of patients evaluated by a dermatologist through either teledermatology or in-person compared with the previous year.Seventy-nine teledermatology consults were placed by 6 PCPs from an outpatient clinic between May and December 2014; 57 (74%) were female and their mean (SD) age was 47.0 (12.4) years. Teledermatology reduced median time to evaluation from 70.0 days (interquartile range [IQR], 33.25-83.0 days) to 0.5 days (IQR, 0.172-0.94 days) and median time to treatment from 73.5 to 3.0 days compared with in-person dermatology visits. Overall, a greater percentage of patients (120 of 144 [83.3%]) were evaluated by a dermatologist through either teledermatology or in-person during the 2014 study period compared with the previous year (111 of 173 [64.2%]). Primary care physicians followed management recommendations 93% of the time.Epic-based SAF teledermatology can improve access to dermatologic care in a public safety-net hospital setting. We hope that the system will serve as a model for other health care organizations wanting to create SAF teledermatology workflows within the Epic EHR system.
TCTAP A-029 Clinical Outcomes of Second-generation Limus-eluting Stents Compared to Paclitaxel-eluting Stents in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction
Authors: Dong-Yi Chen, Chun-Tai Mao, Tien-Hsing Chen
Journal: Journal of the American College of Cardiology (2017)
Patterns of treatment (tx) with bone-modifying agents (BMA) in patients with bone metastases (mets).
Authors: Jane M Quigley, Rohini Khorana Hernandez, Karynsa Cetin, Melissa A. Pirolli, David Quach, Alexander Liede
Journal: Journal of Clinical Oncology (2013)

e20690 Background: Bone mets can lead to serious and debilitating skeletal-related events (SREs: fracture, spinal cord compression, and surgery or radiation to bone). Three BMAs are approved in the US for prevention of SREs in cancer patients (pts) with bone mets: 2 intravenous bisphosphonates (IV BP) with recommended dosing every 3-4 weeks (pamidronate [PAM] and zoledronic acid [ZA]), and 1 RANK ligand inhibitor with subcutaneous injection every 4 weeks (denosumab). Monitoring real-world tx trends is important, particularly as low persistence has been linked to higher rates of SREs (Hatoum et al 2008). Methods: A retrospective cohort was defined from the Oncology Services Comprehensive Electronic Records (OSCER) database, which includes medical records from &gt;500K pts treated at 76 US oncology practices. Adult solid tumor pts with bone mets who initiated tx with a BMA between Jan 2011 and Oct 2011 were included and followed for 12 mos after tx initiation. Pts were either naïve (no BMA in previous 6 mos) or transition (different BMA received in previous 6 mos). Results: The cohort was composed of 1445 denosumab pts (62% naïve) and 1807 IV BP pts (99% naïve). Pt characteristics were similar, although denosumab pts were somewhat more likely to have prostate cancer than IV BP pts (30% vs 25%). Denosumab pts were more likely to receive regular tx during follow-up and less likely to switch tx than IV BP pts (Table). Trends were consistent across tumor types and for naïve vs transition pts. Conclusions: This descriptive analysis reports on tx patterns for pts with bone mets since the availability of denosumab in Dec 2010. Denosumab represented almost half (44%) of pts initiating a BMA and one-third of pts naïve to tx. Uninterrupted tx was more common for denosumab pts than IV BP pts, regardless of tumor type. Trends, including reasons for and consequences of tx interruption, should be monitored as the pt experience develops. [Table: see text]
Non-Small Cell Lung Cancer Mutation Analysis in Purely Caucasian Croatian Population
Authors: Marko Jakopović, Luka Brčić, Marija Mišić, Fran Seiwerth, Gordana Drpa, Branka Čučević, Sanja Pleština, Suzana Kukulj, Mihovil Roglić, Silvana Smojver-Ježek, Nabil Chalfe, Sven Seiwerth, Zoran Janevski, Miroslav Samaržija
Journal: Journal of Thoracic Oncology (2015)
Effect of orthodontic treatment on the periodontal tissues
Authors: Joseph S. Antoun, Li Mei, Kelsi Gibbs, Mauro Farella
Journal: Periodontology 2000 (2017)

Abstract Reduced periodontal support is a challenge that clinicians often face during rehabilitation of compromised dentition. The close and intricate relationship between the periodontal tissues and the processes of tooth movement suggest that adjunct orthodontic therapy may play an important role in overcoming these problems. On the other hand, excessive movement of teeth beyond the anatomic boundaries of the alveolar process is commonly believed to contribute to further destruction of the periodontal tissues. This review evaluates the clinical effects of various orthodontic tooth movements on the surrounding periodontal soft tissues and alveolar bone. Another objective was to identify possible patient and treatment‐related factors that may influence the response of periodontal tissue to specific orthodontic treatments. Particular emphasis is placed on specific tooth movements, such as extrusion, intrusion, space closure and arch expansion. Limitations of current research are also highlighted and discussed.